Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

3D Biomatrix Announces Allowance of U.S. Patent

Published: Thursday, February 06, 2014
Last Updated: Thursday, February 06, 2014
Bookmark and Share
Cell culture technology uniquely addresses 3D spheroid and embryoid body growth challenges.

3D Biomatrix, Inc. announce the Notice of Allowance of its U.S. Patent for technology included in the Perfecta3D  Hanging Drop Plates, a novel platform that makes 3D spheroid and embryoid body growth, along with an array of co-cultures, simple and inexpensive to perform. The patent entitled “Hanging Drop Devices, Systems and/or Methods” covers several core technologies: 

• The development of a complete hanging drop system that allows the performance of cell analysis in individual hanging drops within a standard 96- or 384-well platform. 

• The specific design of the Perfecta3D Hanging Drop Plate, which allows the growth of one spheroid or embryoid body per well without adherence to a plastic surface or other substance. 

• The inclusion of a water or media reservoir that acts as a humidity source to alleviate the commonly-encountered hanging drop evaporation problem. 

Researchers have long tested drug compounds and other factors affecting cell growth on flat surfaces in two dimensions (2D), but 2D cell cultures do not accurately represent how cells behave in the three-dimensional body. 3D cell cultures grown in the Perfecta3D Hanging Drop Plates allow researchers to recapitulate these characteristics in vitro, providing a more physiologically-relevant model. 3D Biomatrix’s Hanging Drop Plates facilitate the consistent and controllable growth of small spherical cellular 3D clusters in a well-plate format, allowing researchers to test compounds and other factors in a 3D environment that reflects the human body. 

3D Biomatrix and the University of Michigan are listed as the assignees of the patent. 3D Biomatrix holds an exclusive license for worldwide rights to the intellectual property covered by this patent. The inventors of the Perfecta3D technology include Shuichi Takayama, a professor having a joint appointment in the Department of Biomedical Engineering and Macromolecular Science and Engineering at the University of Michigan, Yi-Chung Tung, Amy Yu-Ching Hsiao and Edward Jan. Dr. Takayama is a member of 3D Biomatrix’s Scientific Advisory Board. 

“The allowance of this patent is an important milestone, and we will continue to expand our IP portfolio. Life science and drug discovery researchers want more relevant tools in their toolbox. Although the hanging drop technology has been used for decades, the available techniques were difficult to use making it challenging to reproduce results consistently. The 96- and 384-well Perfecta3D Hanging Drop Plates make spheroid growth, long- and short-term cultures, and expansive co-culture models simple to perform and reproduce in 3D,” said 3D Biomatrix CEO Laura Schrader.

"Our worldwide customers include researchers in academia performing cell biology, cancer and stem cell research as well as leading pharmaceutical companies who want to reduce the drug attrition rate by getting more relevant answers earlier in their research process along with the ability to perform high-content analysis and high-throughput screening,” concluded Schrader.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

3D Biomatrix and Cayman Chemical Partner
Companies have partnered to develop and supply a novel assay kit for measuring the viability of cells growing in three-dimensional (3D) spheroids.
Monday, November 25, 2013
Scientific News
New Cancer Drug Target in Dual-Function Protein
Scientists at The Scripps Research Institute (TSRI) have identified a protein that launches cancer growth and appears to contribute to higher mortality in breast cancer patients.
Penn State, TB Alliance, and GSK Partner To Discover New Treatments For TB
A new collaboration between TB Alliance, GSK, and scientists in the Eberly College of Science seeks to find new small molecules that can be used to create antibiotics in the fight against tuberculosis (TB).
Molecular Map Provides Clues To Zinc-Related Diseases
Mapping the molecular structure where medicine goes to work is a crucial step toward drug discovery against deadly diseases.
Platelets are the Pathfinders for Leukocyte Extravasation During Inflammation
Findings from the study could help in the prevention and treatment of inflammatory pathologies.
Genetic Research Can Significantly Improve Drug Development
With drug development costs topping $1.2bn (£850 million) to get a single treatment to the point it can be sold and used in the clinic, could genetic analysis save hundreds of millions of dollars?
New Method Opens Door to Development of Many New Medicines
Findings from TSRI reveal human proteins are better drug targets than previously thought.
Diagnosing Systemic Infections Quickly, Reliably
Team develop rapid and specific diagnostic assay that could help physicians decide within an hour whether a patient has a systemic infection and should be hospitalized for aggressive intervention therapy.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Blood Test That Detects Early Alzheimer’s Disease
A research team, led by Dr. Robert Nagele from Rowan University School of Osteopathic Medicine and Durin Technologies, Inc., has announced the development of a blood test that leverages the body’s immune response system to detect an early stage of Alzheimer’s disease – referred to as the mild cognitive impairment (MCI) stage – with unparalleled accuracy.
A New Approach to Chemical Synthesis
Communesins, originally found in fungus, could hold potential as cancer drugs.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!